# To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

> **NCT04894591** · — · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 272 (actual)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Zepzelca

## Key facts

- **NCT ID:** NCT04894591
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-28
- **Primary completion:** 2025-06-04
- **Final completion:** 2025-06-04
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894591, "To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04894591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*